



27th June, 2024

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 974556 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
--	--

SUB.: Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015:
The Company’s wholly owned subsidiary, CARBOGEN AMCIS AG
successfully completed US FDA Inspection of its manufacturing sites
located in Hunzenschwil (Neuland), Switzerland and Aarau, Switzerland

Dear Sir,

With reference to the captioned subject, we would like to inform that yesterday the Company’s wholly owned subsidiary, CARBOGEN AMCIS AG’s manufacturing sites located in Hunzenschwil (Neuland), Switzerland and Aarau, Switzerland, have successfully completed U.S. Food and Drug Administration (FDA) inspections. The inspections at both the above-mentioned sites were concluded with no Form 483 and classified as No Action Indicated.

Kindly take this on your record & oblige.

Thanking you.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary